First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

In the last decade, drug development has tackled substantial challenges to improve efficiency and facilitate access to innovative medicines. Integrated clinical protocols and the investigation of targeted oncology drugs in healthy volunteers (HVs) have emerged as modalities with an increase in scope...

Descripción completa

Detalles Bibliográficos
Autores principales: Teneggi, Vincenzo, Novotny‐Diermayr, Veronica, Lee, Lay Hoon, Yasin, Maryam, Yeo, Pauline, Ethirajulu, Kantharaj, Gan, Sylvia Bong Hwa, Blanchard, Stephanie E., Nellore, Ranjani, Umrani, Dhananjay N., Gomeni, Roberto, Teck, Darren Lim Wan, Li, Greg, Lu, Qing Shu, Cao, Yang, Matter, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951458/
https://www.ncbi.nlm.nih.gov/pubmed/31343094
http://dx.doi.org/10.1111/cts.12678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951458/
https://www.ncbi.nlm.nih.gov/pubmed/31343094
http://dx.doi.org/10.1111/cts.12678

Ejemplares similares